Back

iRhythm Technologies Announces Third Quarter 2017 Financial Results and Raises Guidance for Full Year 2017

SAN FRANCISCO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three and nine months ended September 30, 2017.

Recent Highlights

  • Revenue for the quarter ended September 30, 2017 increased 49% year-over-year to $25.0 million
  • Gross margin for the third quarter 2017 was 72% versus 69% in the third quarter of 2016

“Third quarter and year-to-date performance highlight the progress we are making in establishing our Zio Service as the new standard of care for ambulatory cardiac monitoring,” said Kevin King, CEO. "This consistent growth in demand has enabled us to confidently expand our salesforce and infrastructure throughout 2017, as well as make significant progress in growing in-network coverage, which has meaningfully increased our productivity and volume.”

Third Quarter Financial Results
Revenue for the three months ended September 30, 2017 was $25.0 million, an increase of 49% year-over-year and 5% sequentially.  Revenue growth remains predominantly driven by increased volume of the Zio Service in both new and existing accounts, as well as continued success with in-network contracting efforts.

Gross profit for the third quarter of 2017 was $18.1 million, or 72% gross margin, up from $11.5 million, or 69% gross margin, in the same period of the prior year. Margin expansion is primarily attributable to productivity gains through the company’s machine-learned algorithms associated with report generation, the impact from the mix shift to contracted claims, and continued reduction of device-related manufacturing costs.

Operating expenses for the third quarter of 2017 were $24.1 million, an increase of 70% compared to $14.2 million for the same period of the prior year. The increase in operating expenses was primarily driven by accelerated salesforce expansion investments and a material increase in stock-based compensation.

Loss from operations for the third quarter of 2017 was $6.5 million, compared to $4.1 million for the same period of the prior year.

Cash, cash equivalents, and investments totaled $107.4 million as of September 30, 2017.

Guidance for Full Year 2017
iRhythm projects revenue for the full year 2017 to range from $96 to $97 million, gross margins for the full year 2017 to range from 71.5% to 72.5% and operating expenses for the full year 2017 to be between $93 and $95 million. This compares to previous guidance of $94 to $96 million in revenue, 71.5% to 72.5% in gross margins, and $89 and $92 million in operating expenses for the full year 2017 provided on August 2, 2017.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, and referencing Conference ID: 96279903 or from the webcast on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding expectations for expansion in our salesforce, increases in our in-network contracting and financial guidance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our Form 10-Q filing made with the Securities and Exchange Commission on August 7, 2017. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
investors@irhythmtech.com

Media Contact
Aaron Murphy
(415) 229-3331
media@irhythmtech.com

 

 

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)

    September 30, 2017   December 31, 2016
Assets        
Current assets:        
Cash and cash equivalents   $ 20,429     $ 51,643  
Short-term investments     87,017       54,407  
Accounts receivable, net     12,039       9,406  
Inventory     1,314       1,390  
Prepaid expenses and other current assets     1,989       1,671  
Restricted cash           91  
Total current assets     122,788       118,608  
Investments, long-term           10,981  
Property and equipment, net     6,207       4,653  
Goodwill     862       862  
Other assets     3,798       3,052  
Total assets   $ 133,655     $ 138,156  
Liabilities, Convertible Preferred Stock and Stockholders’ Equity        
Current liabilities:        
Accounts payable   $ 2,076     $ 2,103  
Accrued liabilities     11,436       10,165  
Deferred revenue     904       947  
Accrued interest, current portion     149        
Debt, current portion     1,479        
Total current liabilities     16,044       13,215  
Debt     32,053       32,227  
Deferred rent, noncurrent portion     169       26  
Accrued interest, net of current portion           126  
Total liabilities     48,266       45,594  
Stockholders’ equity:        
Common stock     28       22  
Additional paid-in capital     230,831       219,718  
Accumulated other comprehensive loss     (30 )     (9 )
Accumulated deficit     (145,440 )     (127,169 )
Total stockholders’ equity     85,389       92,562  
Total liabilities and stockholders’ equity   $ 133,655     $ 138,156  
                 

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2017       2016       2017       2016  
Revenue $ 25,035     $ 16,780     $ 70,327     $ 45,368  
Cost of revenue   6,920       5,282       20,002       15,097  
Gross profit   18,115       11,498       50,325       30,271  
Operating expenses:              
Research and development   3,790       1,635       9,187       4,847  
Selling, general and administrative   20,308       12,529       57,787       36,658  
Total operating expenses   24,098       14,164       66,974       41,505  
Loss from operations   (5,983 )     (2,666 )     (16,649 )     (11,234 )
Interest expense   (862 )     (807 )     (2,522 )     (2,388 )
Other expense, net   321       (602 )     900       (1,015 )
Net loss $ (6,524 )   $ (4,075 )   $ (18,271 )   $ (14,637 )
Net loss per common share, basic and diluted $ (0.29 )   $ (2.80 )   $ (0.81 )   $ (10.20 )
Weighted-average shares used to compute net loss per common share, basic and diluted   22,811,907       1,454,307       22,446,399       1,434,583  

 

 

CONTACT US FOR MORE INFORMATION